283 related articles for article (PubMed ID: 25088482)
21. [Premature ovarian failure after chemotherapy for breast cancer].
Mathelin C; Brettes JP; Diemunsch P
Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
[TBL] [Abstract][Full Text] [Related]
22. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
23. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
24. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report].
Asaga S; Ando J; Arai T; Fujii H
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976
[TBL] [Abstract][Full Text] [Related]
25. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
26. Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females.
Potolog-Nahari C; Fishman A; Cohen I
Gynecol Endocrinol; 2007 May; 23(5):290-4. PubMed ID: 17558688
[TBL] [Abstract][Full Text] [Related]
27. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
Robertson JF; Blamey RW
Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
[TBL] [Abstract][Full Text] [Related]
28. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
29. Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity.
Garrido-Oyarzún MF; Castelo-Branco C
Climacteric; 2016 Dec; 19(6):522-525. PubMed ID: 27644002
[TBL] [Abstract][Full Text] [Related]
30. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report.
Pereyra Pacheco B; Méndez Ribas JM; Milone G; Fernández I; Kvicala R; Mila T; Di Noto A; Contreras Ortiz O; Pavlovsky S
Gynecol Oncol; 2001 Jun; 81(3):391-7. PubMed ID: 11371127
[TBL] [Abstract][Full Text] [Related]
31. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
[TBL] [Abstract][Full Text] [Related]
32. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
34. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
35. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
Badawy A; Elnashar A; El-Ashry M; Shahat M
Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
[TBL] [Abstract][Full Text] [Related]
36. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
37. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
39. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
40. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
